Combination of ibrutinib plus venetoclax with MRD-driven duration of treatment results in a higher rate of MRD negativity in IGHV unmutated than mutated CLL: Updated interim analysis of FLAIR study

Updated interim analysis focused on MRD results from the FLAIR study, an ongoing multicenter phase III trial with multiple cohorts, demonstrates that patients with untreated CLL who received combination of ibrutinib plus venetoclax demonstrate moderate to high rates of undetectable MRD in the bone marrow within 24 months. The FLAIR study uses serial MRD testing to determine treatment duration, which is defined as twice the time to MRD negativity. Patients with unmutated IGHV were more likely to demonstrate undetectable MRD in the bone marrow at 24 months compared to individuals with mutated IGHV (79.4% vs. 56.4%; OR 3.60; 95% CI: 1.59 - 8.15, p = 0.0022).